Company Overview
Company Type: Public Company
Website: rapid-dose.com
Number of Employees: -
Ticker: DOSE (CNSX)
Year Founded: -


Business Description
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active molecule into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system, as well as dental products. It also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. Rapid Dose Therapeutics Corp. is headquartered in Burlington, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.9
Market Capitalization
13.0
TEV/Total Revenue
16.4x
EBITDA
(2.7)
Total Enterprise Value
14.7
TEV/EBITDA
NM
EBIT
(3.0)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(3.4)
Total Debt
1.8
Price/Tang BV
NM
Total Assets
2.1
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of May-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Upsdell, Mark Andrew
Founder, President, CEO & Director
Hyland, Douglas Alan
Chief Financial Officer
Macphail, Ben 
Chief Scientist
Sheldon, Donald Alexander-R.
Legal Counsel
Lewis, Jason 
Senior Vice President of Business Development
Kapadia, Rishi 
Controller
Estepa, Jorge 
Assistant Corporate Secretary

Key Board Members
Name
Title
Upsdell, Mark Andrew
Founder, President, CEO & Director
Hasler, Peter-Thilo 
Independent Director
Brooks, Ron 
Member of Advisory Board
Cornacchia, Marisa 
Independent Director
Glogauer, Michael 
Member of Advisory Board
Hrudka, Christine Jean
Independent Director
Lachance, Anne 
Member of Advisory Board
McKimm, John M.
Independent Director
Tytus, Richard 
Member of Advisory Board
DiRenzo, Nicholas 
Member of Advisory Board


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
1121 Walkers Line Unit 3A | Burlington, ON | L7N 2G4 | Canada
Phone: (416) 477-1052   

Current and Pending Investors
Tilray Brands, Inc. (NasdaqGS:TLRY)

Prior Investors
Goodbody Health Limited (OTCPK:GDBY.F)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.10
Market Cap (mm)
13.0
Open
 0.11
Shares Out. (mm)
103.9
Previous Close
 0.13
Float %
88.5%
Change on Day
(0.03)
Shares Sold Short (mm)
-
Change % on Day
(20.0)%
Dividend Yield %
-
Day High/Low
 0.11/ 0.10
Diluted EPS Excl. Extra Items
(0.03)
52 wk High/Low
 0.21/ 0.09
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.04
Beta 5Y
1.21


 
Delayed Quote** | Last Updated on Oct-06-2023 11:34 AM (GMT-5)
CNSX:DOSE - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
2544737 Ontario Limited
As of March 19, 2021, 2544737 Ontario Limited operates as a subsidiary of Rapid Dose Therapeutics Corp.

United States and Canada
Pharmaceuticals
-
-
-
ACME Resources Corp.
As of December 7, 2018, ACME Resources Corp. was acquired by Rapid Dose Therapeutics Inc., in a reverse merger transaction. ACME Resources Corp. does not have significant operations. It intends to identify, evaluate, and acquire assets, properties, or businesses with a view to complete a qualifying transaction. The company was incorporated in 2008 and is based in Toronto, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00
RDT Therapeutics Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-02-2023
-
Private Placement
Target
Rapid Dose Therapeutics Corp. (CNSX:DOSE)


3.72
May-26-2022
Aug-10-2022
Private Placement
Target
Rapid Dose Therapeutics Corp. (CNSX:DOSE)


0.18
May-25-2022
May-25-2022
Private Placement
Target
Rapid Dose Therapeutics Corp. (CNSX:DOSE)


0.12
Jan-11-2021
Mar-19-2021
Merger/Acquisition
Buyer
2544737 Ontario Limited
Rapid Dose Therapeutics Corp. (CNSX:DOSE)

3.91
Mar-05-2020
-
Private Placement
Target
Rapid Dose Therapeutics Corp. (CNSX:DOSE)


7.46
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-22-2023
Executive/Board Changes - Other
Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of Directors
Aug-01-2023
Annual General Meeting
Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023
Jun-28-2023
Auditor Going Concern Doubts
Rapid Dose Therapeutics Corp. Auditor Raises 'Going Concern' Doubt
Jun-02-2023
Private Placements
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in funding
May-17-2023
Auditor Changes
Rapid Dose Therapeutics Corp. Announces Change of Auditor


Advisors
Most Recent Auditor
Chartered Professional Accountants of Bermuda


Most Recent Auditor
Chartered Professional Accountants


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Sphene Capital GmbH
Hasler, Peter-Thilo
Oct 15, 2019 12:34 AM
DOSE
An Innovative Drug Delivery Platform
Initiation of Coverage*
63


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Upsdell, Mark Andrew

11,930,247

11.49

1.5

Jul-24-2023


Hrudka BA BSP, Christine Jean

3,000

0.00

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Hrudka BA BSP, Christine Jean
3,000
3,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Campaign and Content Services, Infused Soaps, Licensing of QuickStrip, Product Innovation Services, Production and Consultation Services, QuickStrip, XyliStrip


Upcoming Events
Date/Time
Type
Oct-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Oct-05-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
News Releases
187 KB
Oct-02-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
Material Change Report
285 KB
Sep-22-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
News Releases
191 KB
Sep-14-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
News Releases
175 KB
Aug-09-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
News Releases
179 KB
Jul-28-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
Interim Financial Statements
460 KB
Jul-26-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
Securities Acquisition Filings (Early Warning)
233 KB
Jul-26-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
Material Change Report
281 KB
Jul-07-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
News Releases
257 KB
Jul-06-2023
Rapid Dose Therapeutics Corp. (CNSX:DOSE)
SEDAR
Management Proxy Materials
167 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Upsdell, Mark Andrew (Founder, President, CEO & Director)
Jan-27-2022
Common Shares
1,000
312
Open Market Acquisition
0.01
Multiple
Enerdynamic Systems Inc.
Mar-19-2021
Common Shares
4,965,986
0
Open Market Acquisition
New
Exchange Announcement
Howlett B.Comm., C.M.A., CPA, CMA, Brian Michael (Former Independent Director)
Dec-04-2019
Common Shares
(20,500)
(10,393)
Open Market Disposition
(8.63)
Exchange Announcement
Lewis, Jason  (Senior Vice President of Business Development)
Oct-31-2019
Common Shares
85,000
61,847
Private Acquisition
1.79
Exchange Announcement
Howlett B.Comm., C.M.A., CPA, CMA, Brian Michael (Former Independent Director)
Apr-04-2019
Common Shares
(2,500)
(1,997)
Open Market Disposition
(1.04)
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Upsdell, Mark Andrew
Founder, President, CEO & Director
(416) 477-1052
-
mupsdell@rapid-dose.com
Hasler, Peter-Thilo 
Independent Director
49 152 31 76 45 53
-
peter-thilo.hasler@sphene-capital.de
Brooks, Ron 
Member of Advisory Board
(416) 477-1052
-

Cornacchia, Marisa 
Independent Director
(416) 477-1052
-

Glogauer, Michael 
Member of Advisory Board
(416) 477-1052
-

Hrudka, Christine Jean
Independent Director
(416) 477-1052
-

Lachance, Anne 
Member of Advisory Board
(416) 477-1052
-

McKimm, John M.
Independent Director
(888) 939-8885  2354
-
john.mckimm@seb-inc.com
Tytus, Richard 
Member of Advisory Board
(416) 477-1052
-

DiRenzo, Nicholas 
Member of Advisory Board
(416) 477-1052
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Upsdell, Mark Andrew
Founder, President, CEO & Director
(416) 477-1052
-
mupsdell@rapid-dose.com
Hyland, Douglas Alan
Chief Financial Officer
(416) 477-1052
-

Macphail, Ben 
Chief Scientist
(416) 477-1052
-

Sheldon, Donald Alexander-R.
Legal Counsel
416-595-0147
416-865-1398
DSheldon@dickinsonwright.com
Lewis, Jason 
Senior Vice President of Business Development
(416) 477-1052
-

Kapadia, Rishi 
Controller
(416) 477-1052
-

Estepa, Jorge 
Assistant Corporate Secretary
416.818.4035
-
jestepa@rapid-dose.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
